A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Authors:
- Bin CaoBCBin Cao
- Yeming WangYWYeming Wang
- Danning WenDWDanning Wen
- Wen LiuWLWen Liu
- Jingli WangJWJingli Wang
- Guohui FanGFGuohui Fan
- Lianguo RuanLRLianguo Ruan
- Bin SongBSBin Song
- Yanping CaiYCYanping Cai
- Ming WeiMWMing Wei
- Xingwang LiXLXingwang Li
- Jiaan XiaJXJiaan Xia
Top Cited Papers
Open Access
- 7 May 2020
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (19) , 1787-1799
Abstract
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72). Mortality at 28 days was similar in the lopinavir–ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, −5.8 percentage points; 95% CI, −17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir–ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir–ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir–ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.)Keywords
This publication has 22 references indexed in Scilit:
- Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimenInternational Journal of Antimicrobial Agents, 2014
- Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell CultureAntimicrobial Agents and Chemotherapy, 2014
- Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dataThe Lancet Respiratory Medicine, 2014
- Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assaysJournal of General Virology, 2014
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09Clinical Infectious Diseases, 2012
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- Small molecules targeting severe acute respiratory syndrome human coronavirusProceedings of the National Academy of Sciences, 2004
- HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirusBiochemical and Biophysical Research Communications, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004